Phospha E linked to healthy cardiovascular function

Melbourne's Phosphagenics (ASX:POH) has found its vitamin product Phospha E has reduced LDL-C (bad cholesterol) concentrations in blood by up to 44 per cent in an animal study.

"Based on these animal studies, as well as earlier in vitro studies, we are confident in the potential of Phospha E to support cardiovascular health in humans," said Phosphagenics director of research and development Esra Ogru in a statement. "Phosphagenics intends to commence clinical trials in humans to provide further support for the product's health benefits, including its effect on cardiovascular health."

Phospha E was also found to reduce another heart disease risk factor, plasma triglycerides, by up to 51 per cent in mice fed normal diets. When fed high cholesterol diets, Phospha E significantly reduced plaque formation in the aorta by 58 per cent. In contrast, regular vitamin E had no significant effect on plaque formation, or cholesterol levels.